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Abstract Stroke remains a significant unmet condition in the
USA and throughout the world. To date, only approximately
3% of the population suffering an ischemic stroke benefit from
the thrombolytic drug tissue plasminogen activator, largely due
to the drug’s narrow therapeutic window. The last decade has
witnessed extensive laboratory studies suggesting the thera-
peutic potential of cell-based therapy for stroke. Limited
clinical trials of cell therapy in stroke patients are currently
being pursued. Bone marrow-derived stem cells are an
attractive, novel transplantable cell source for stroke. There
remain many unanswered questions in the laboratory before
cell therapy can be optimized for transplantation in the clinical
setting. Here, we discuss the various translational hurdles
encountered in bringing cell therapy from the laboratory to the
clinic, using stem cell therapeutics as an emerging paradigm for
stroke as a guiding principle. In particular, we focus on the
preclinical studies of cell transplantation in experimental stroke
with emphasis on a better understanding of mechanisms of
action in an effort to optimize efficacy and to build a safety
profile for advancing cell therapy to the clinic. A forward
looking strategy of combination therapy involving stem cell
transplantation and pharmacologic treatment is also discussed.
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Introduction
Stroke continues to be a major cause of death in the
USA and throughout the world. Due to treatment
options for stroke being limited to tissue plasminogen
activator (tPA), a surge in novel therapies, such as stem
cell transplantation, has been explored in the laboratory.
Over the last decade, stem cell therapy has shown
promise as an experimental treatment for stroke [1–3].
The first clinical trial implementing cell therapy as a
treatment for stroke occurred in 1998 [4]. In the last
2 years, the US Food and Drug Administration (FDA) has
approved limited clinical trials of cell therapy in stroke
patients. Bone marrow-derived stem and progenitor cells
represent a major donor cell source for transplantation.
Along the lines of stroke treatment academic industry
roundtable (STAIR) recommendations for translating
pharmacologics from the laboratory to the clinic, the stem
cell therapeutics as an emerging paradigm for stroke
(STEPS) has been advanced as a guiding principle for
cell therapy in stroke. Here, we discuss preclinical studies
of cell transplantation in experimental stroke with empha-
sis on bone marrow-derived stem cells using STEPS as a
yardstick in building the efficacy and safety profile of this
cell therapy for clinical application.
The Many Faces of Bone Marrow-Derived Stem Cells
The bone marrow consists of a heterogeneous population of
stem cells, namely hematopoietic stem cells (HSCs) and
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mesenchymal stem cells (MSCs) [5]. Endothelial progenitor
cells (EPCs) and very small embryonic-like stem cells
(VSELs) have also been isolated from the bone marrow.
Previous studies have discussed the potential of bone
marrow-derived stem cells to differentiate into neurons in
vitro [6], and their secretion of growth factors crucial to
neuronal survival [7–9]. Interest in utilizing bone marrow-
derived stem cells as a therapy for stroke has increased as
researchers look to cell therapy as a treatment for stroke.
A central characteristic of HSCs is their ability to
repopulate removed bone marrow [10]. HSCs remain
quiescent and low in number during homeostasis, but can
quickly proliferate and become mobile in response to injury
[11–13]. The SDF-1/CXCR4 chemoattractant pathway is
crucial for HSC mobilization and migration. Activation of
this pathway stimulates the migration of HSCs from the
bone marrow into the circulation [14].
Mesenchymal stem cells were first defined as a
population of plastic-adherent fibroblastic cells isolated by
Percoll density centrifugation [15]. Human MSCs do not
express the hematopoietic surface markers CD34 and
CD45, but they do express CD13, Stro-1, CD105 (SH2),
and SH3. The therapeutic potential of MSCs lies in their
ability to differentiate into mesodermal lineages, such as
skeletal myoblasts, fibroblasts, osteoblasts, adipocytes, and
chondroblasts both in vitro and in vivo [16–20] (Table 1).
MSCs utilized in experimental stroke models have im-
proved the functional recovery of neurological deficits
caused by cerebral ischemia [49–58]. Clinical reports of
MSC transplantation in stroke patients reveal that MSCs
may improve the functional recovery of patients without
adverse side effects [49]. The underlying therapeutic
mechanism through which MSCs offer therapeutic benefit
remains unclear.
Very small embryonic-like cells are present in many
adult organs expressing progenitor stem cell markers [46].
The brain contains a relatively high number of cells that
display the VSEL phenotype [47, 59]. VSELs are smaller
than erythrocytes and can be purified from umbilical cord
blood and mobilized peripheral blood. VSELs are recognized
as very small cells belonging to the non-hematopoietic portion
of leukocytes, expressing CD34, CD133, and CXCR4
antigens [46, 48] and are mobilized into the peripheral blood
following injury.
EPCs are immature endothelial cells circulating in the
peripheral blood. EPCs are an important component of the
vascular system, as they mature into endothelial cells [21–
25]. Asahara and colleagues transplanted EPCs isolated
from human umbilical cord blood into animal models of
ischemia. The transplanted EPCs were found in the
endothelium of newly formed vessels in the ischemic
regions [21]. EPCs are hematopoietic in origin and can be
found in the peripheral blood of adults and can also be
isolated from human umbilical cord blood [60, 61]. Both
animal and human studies suggest that EPCs principally
participate in re-endothelialization during the neovasculariza-
tion of ischemic organs. These findings suggest that EPC
modulation can be focused toward the therapy of cerebrovas-
cular diseases [21, 22, 25, 26, 61, 62] (Table 1).
HSCs, MSCs, and VSELs can all be categorized as
donor cells primarily aimed toward rescuing the stroke
damaged cells and ischemic cells within the parenchyma.
While rescuing the ischemic penumbra is important, these
cells do not address the issue of the damaged microvascu-
lature. To this end, EPCs are unique in that they target the
leaky vasculature. By repairing the broken blood brain
barrier (BBB), EPCs may aid in the recovery from stroke
and abrogate the immunological attack on the brain and its
Table 1 Target diseases and phenotypes of EPCs, MSCs, hTERT-MSCs, HSCs, and VSEL cells
BM cells Target disease Phenotype References
EPCs Retinal ischemia, Parkinson’s disease, malignant tumors, chronic obstructive, pulmonary
disease, ischemic stroke, traumatic brain injury, and Alzheimer’s disease
Endothelial cells [21–31]
MSCs Malignant tumors and cancer, inflammation, autoimmune, asthma, neurological damage
and regeneration (stroke, Alzheimer, Parkinson, traumatic brain injury, spinal cord
injury), cardiac-related disease (i.e., ischemic cardiomyopathy, myocardial infarction),
inflammatory bowel, multiple sclerosis, and liver regeneration
OCA cells [32–35]
OCA cells [36, 37]
OCA cells [18]
OCA cells [38–40]
OCA cells [41, 42]
OCA cells [43–45]
hTERT-MSCs Cerebral ischemia and spinal cord injury OCA cells [42]
HSCs Alzheimer’s disease, traumatic brain injury, myeloid leukemia, sickle cell anemia,
and cutaneous repair
CD34+ and CXCR4+ [10–13]
VSEL Cells Tissue rejuvenation, stroke, myocardial infractions, diabetes, and cutaneous repair Tree germ lineages [46–48]
OCA cells osteogenic, chondrogenic, and adipogenic cells
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microvasculature (Fig. 1). Due to their ability to differen-
tiate into endothelial cells, EPCs may be the ideal choice
for cell transplantation in BBB repair.
Due to laboratory findings suggesting the angiogenic
and vasculogenic potential of EPCs, clinical studies have
been initiated to determine if patients with ischemic events
may benefit from EPC administration [63]. Studies have
also been initiated to determine if patients with lower
numbers of EPCs are at an increased risk of atherosclerotic
events. Here, we discuss the therapeutic potential of EPCs,
as well as the hurdles faced when translating EPC therapy
from the laboratory to the clinic.
Crossing the Great Divide: Cell Therapy
at the Crossroad of Laboratory and Clinic
Our team together with stem cell-based stakeholders from
academic and industry, as well as federal agencies such as
NIH and FDA, has supported the STEPS consortium in an
effort to improve the successful translation of cell therapy
in stroke from the laboratory to the clinic [3]. Both
clinicians and researchers acknowledge that no two strokes
are the same, underscoring the heterogeneity of the disease.
Although ischemic stroke is the target of cell therapy over
hemorrhagic stroke, ischemic stroke is plagued with several
subtypes ranging from infarcted brain areas to cell death
mechanisms. Only recently have laboratory studies attemp-
ted to encompass these various strokes in animal models
[64]. The most commonly used model for stroke is focal
ischemia in rats or mice. The cell death pathways and
damaged brain regions after focal ischemia can be
manipulated by using permanent, transient, proximal, or
distal occlusion/ligation of the middle cerebral artery. In an
effort to study the heterogeneity of stroke, multiple strains,
age, gender, varying stroke severity, and at least two focal
ischemia models should be utilized in the laboratory to test
the safety and efficacy of cell therapy [1, 3]. Testing cell
therapy in a larger, non-human primate model may be
needed due to the white matter injury associated with stroke
[3, 65–67], which is not well characterized in the rodent
model (Fig. 2). Other transplantation regimen issues, such
as donor cell size which may cause microembolism, and
toxicology readouts which may be better studied in a non-
human primate model, may similarly necessitate testing of
cell therapy in large animal model.
Route of administration is also an important factor that
needs to be taken into consideration when translating cell
therapy from the laboratory to the clinic. Although
intravenous (IV) cell delivery is a minimally invasive
procedure, it is traditionally only employed in acute stroke
models, limiting the population that may benefit from cell
therapy. IV cell transplantation requires a higher cell dose,
which may cause the formation of microembolisms. Intra-
arterial (IA) cell delivery is also minimally invasive, but is
typically only employed in acute stroke models to take
advantage of the stroke-induced upregulation of chemo-
attractant pathways that aid in the migration of stem cells
from the periphery to the brain. IA cell delivery may
circumvent the formation of microembolisms by requiring a
lower cell dose. Intracerebral (IC) cell transplantation can
be employed in both the acute and chronic stages of stroke.
However, IC cell delivery is an invasive procedure that
requires a neurological surgery service, limiting the acute
stroke patient population that would have access to this
type of cell transplantation.
Better Safe than Sorry: Safety Profile of Stem Cells
In addition to demonstration of efficacy via behavioral
testing, building a safety profile is an equally important
Fig. 1 BBB repair via EPC transplantation post-ischemic injury.
Under normal conditions, the BBB is intact (a). The integrity of the
BBB becomes compromised after stroke, allowing immune cells to
enter the brain parenchyma (b). EPCs migrate from the periphery to
the site of injury (c). Once at the area of injured vasculature, the EPCs
aid in repairing the compromised BBB, potentially attenuating stroke
pathogenesis (d)
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gating item prior to proceeding to clinical trials of stem cell
therapy. Along this line, EPCs have had a recent history of
safety in the clinic. Clinical studies have been initiated to
determine whether patients with lower numbers of EPCs
are at an increased risk of atherosclerotic events, and
whether patients with ischemic events may benefit from
EPC administration [68]. To date, clinical studies support
the therapeutic potential of EPC transplantation; however,
this assumption should be approached with much caution
due to these studies being open label trials, observational
and/or anecdotal accounts, and a limited number of
patients.
Clinical studies of EPC in neurovascular disease are
much very limited, with only three observational
studies in patients with stroke. In 25 patients with an
ischemic stroke, CD34+ cells peaked 7 days after
stroke but generally reverted to baseline after 30 days
[69]. Interestingly, higher CD34+ cell levels at 30 days
related to an increased number of infarcts on magnetic
resonance imaging and also to worse cerebrovascular
function, as measured with positron emission tomography
scanning (cerebral metabolic rate of oxygen, and cerebral
blood flow). On the other hand, decreased numbers of
clusters of rapidly adhering cells were seen after stroke
and in “stable cerebrovascular disease,” compared with
controls free of vascular disease [24]. Cerebrovascular
disease and higher age, in general, independently related
to lower EPC numbers. These discrepancies in results
may be from mismatched controls for patient age and/or
the lack of methodological design for testing specific
hypotheses on the causal role of EPC in cerebrovascular
disease [24].
The Changing Landscape of Cell-Based Therapeutic
Targets: Intraparenchymal Versus Extraparenchymal
Rescue of the Stroke Brain
A major STEPS requirement is to demonstrate a
specific set of phenotypic markers unique to the stem
cell under investigation [3]. EPCs were first isolated
from human peripheral blood and express shared markers
with HSCs, angioblasts, and receptors for vascular
endothelial growth factor (VEGFR2/KDR) [21]. Immu-
nological surface markers and functional profiling via
colony formation capacity have been utilized to determine
EPC characteristics [26–29, 70]. Various markers, such as
CD31, VE-cadherin, E-selectin, von Willebrand factor
and eNOS, have been employed to harvest EPCs [21, 26,
28, 70, 71]. Equally solid evidence suggests that only
CD34-positive EPCs isolated form umbilical cord blood
or bone marrow posses the ability to differentiate into
Fig. 2 Translational steps from
the laboratory to the clinic. Two
focal ischemia models in rodents
should be utilized to determine
optimal timing, dose, and route
of administration. Functional
recovery should also be tested in
the rodent models. Once these
factors have been established in
the rodent models, the cell
therapy may require further
validation in a larger animal
model, especially when critical
stroke readouts (e.g., white
matter) cannot be determined in
the rodents. Limited clinical
trials may proceed in tandem
with the preclinical studies once
safety profile and efficacy
outcomes are demonstrated in
the laboratory
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mature endothelial cells [25, 68, 72]. Recent studies have
employed the HSC specific AC133 surface marker to
isolate EPCs [26, 29]. Double labeling with CD34 and
VEGFR2 is the marker of choice for obtaining a highly
homogenous population of EPCs [26, 29, 73]. Functional
profiling of EPCs is performed by counting the number of
colonies formed after 7 days of culture. A colony consists
of a central cluster of rounded cells with surrounding
radiating thin, flat cells [21, 73–75]. These colonies
express many endothelial characteristics, including
CD31, VEGFR2, and Tie-2 [21, 75]. Although character-
ization of EPCs in cell culture remains challenging, the
unique properties of these cells as described by Finkel
and co-workers [68] may suffice as a starting point in
delineating this novel BM cell population. This can be
assessed by expression profiles, functional characteristics,
and regenerative capacity, especially for promoting
vasculogenesis and/or vascular homeostasis [68].
Making the Correct STEPS in Designing
the Experiments
After confirming the stem cell phenotype, the optimal
cell transplantation regimen should be examined. When
designing an experimental model, the research design
should closely approximate the envisioned clinical
application. Optimization of cell dose, delivery route,
and timing of administration are the three most crucial
factors that needed to be determined in the laboratory.
Based on the optimization results obtained in the
laboratory, the next critical step is to determine whether
these factors are feasible in the clinical setting. For
instance, if stereotaxic transplantation of cells immedi-
ately following stroke was found to be a prerequisite for
therapeutic benefit, then such intervention is obviously
limited to patients who are able to reach a medical
center with neurosurgical service. The delivery of cells
via the periphery may likely require the need for
chemotaxic signaling between the host ischemic brain
and the transplanted cells, a scenario that may best
benefit the acute or sub-acute phase of stroke rather
than the stable, chronic stage when the chemokines/
cytokines acting as cues for cell migration may not be
that upregulated. With this in mind, EPCs are crucial
for vasculogenesis and angiogenesis, thus potentially
facilitating BBB repair post-ischemic injury. Accordingly, it is
critical to elucidate the BBB breakdown cascades after
stroke in order to identify the peak period when to
initiate strategies designed to abrogate further vascula-
ture damage and retard stroke progression. These factors
must be considered when designing an experimental
design for clinical translation.
To See is to Believe: Functional Readouts of Cell
Transplants
Next, STEPS requires that a battery of functional tests be in
place to accurately define the therapeutic benefits of stem
cells in stroke [3]. A series of behavioral tests following
ischemic injury and EPC transplantation will likely allow
for closer approximation of clinical improvement associated
with this cell therapy. Somatosensory and motor deficits are
well documented in the rodent model of ischemic injury
[31, 75–78] and there is a growing trend toward the
assessment of cognitive deficits. Alterations in cognitive
behaviors can be assessed when cognitive areas of the brain
are damaged by stroke, thus not all animals suffering from
ischemic stroke, particularly the animals with localized
damage sparing the hippocampus or specific areas of the
basal ganglia, may not be the appropriate subjects for
cognitive testing. Nonetheless, cognitive deficits may arise
even when the hippocampus or other learning and memory
areas are not affected by stroke, thus caution needs to be
taken in delineating motor dysfunctions from cognitive
impairments, as well as examining the brain region
responsible for such cognitive alterations. Long term testing
(i.e., at least 1 month) should be performed to elucidate
whether functional recovery following cell therapy is stable
or temporary. In contemplating with behavioral assessment
of animals suffering stroke transplanted with EPCs, a novel
aspect will be to test the hypothesis whether BBB repair
can augment vasculogenesis and neurogenesis, among other
neuroregenerative processes, in promoting functional re-
covery in stroke. Extensive behavioral testing after stroke
and EPC transplantation is crucial in determining the
efficacy of EPC transplantation, but also should facilitate
a better understanding of mechanism of action of cell
therapy (see further discussion below).
What Is in a Name? Mechanisms of Action Underlying
Cell Therapy
In recent years, the US FDA has shown keen interest in the
mechanism of action underlying stem cell therapy. Until
now, safety and efficacy are the main parameters required
by the FDA for IND applications. Evidence suggests that
stroke, at least the secondary cell death, is closely
associated with a wave of immunological attack upon the
brain and/or its vasculature. Whether EPCs abrogate this
immunological response following stroke remains uncer-
tain. Widespread inflammatory reactions caused by stroke
may trigger a cascade of events, which alter the integrity of
the BBB, resulting in migration of leukocytes into the
central nervous system. Leukocyte transmigration across
the BBB during stroke-mediated immune processes may
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influence inter-endothelial junctional complex function
leading to damage to the vascular endothelium and BBB
breakdown. The disruption or dysfunction of the BBB may
be a key initial factor in stroke pathogenesis, a key
component of Manaenko and colleague’s [79] hypothesis.
EPCs may aid in ameliorating an immunological attack on
the brain and its microvasculature by repairing the damaged
BBB. Increasing the integrity of the BBB post-ischemic
injury may aid in halting the progression of stroke
pathogenesis, possibly leading to a better outcome. Thus,
the study highlights the need for EPCs as transplantable
cells for stroke therapy as the restoration of BBB integrity
may play a critical role in preventing stroke progression.
The mechanisms of action underlying the beneficial
effects of stem cells, in particular EPCs, are not fully
understood. Two proposed mechanisms in which BM-
derived stem cells are believed to exert therapeutic benefits
are through cell replacement and trophic factor secretion.
Although studies utilizing BM typically focused on cell
replacement therapy, the secretion of trophic factors has
become an increasingly important concept in the field of
cell therapy. Trophic factors help promote angiogenesis and
neurogenesis and may aid in rescuing the ischemic
penumbra in stroke.
When translating cell therapy to the clinic, it is important
to understand and identify the mechanisms of action in
order to determine if there are possible safety risks to the
patient. Cell signaling, secretion of growth factors, and
graft-host synaptic connections may provide insights into
stem cell-mediated repair of the stroke brain. Thus,
targeting these pathways can then be used for the tracking
and imaging of the transplanted cells. Imaging, in particular
functional magnetic resonance imaging, has been utilized to
determine graft response post-transplantation [80, 81].
These tools are becoming more widespread and frequent
in determining the pathway, efficacy, and safety of cell
transplantation in both the laboratory and the clinic.
Future Directions: Stem Cell Therapy Joining Forces
with Small Molecule Treatment
The STEPS guidelines are an offshoot of the STAIR
criteria. Here, we present a merger of STEPS and
STAIR whereby a neuroprotective drug may be tested in
the rigorous parameters of STAIR in tandem with stem
cells using the STEPS guidelines. Combination therapies
involving stem cells and drugs may provide a more
robust stroke outcome over stand-alone treatments. As
discussed above, tPA has a very narrow therapeutic
window of 3 h after stroke onset. Furthermore,
deleterious side effects of tPA, in particular bleeding
and hemorrhagic transformation, can exacerbate stroke
injury and counteract its benefits of reperfusion of the
occluded artery. FDA-approved drugs such as albumin
and minocycline (a tetracycline antibiotic) are only
recently being explored in the clinic for their off-
target, neuroprotective treatments in stroke. Because
tPA is already an FDA-approved drug for stroke,
finding strategies designed to extend its therapeutic
window is a highly logical lab-to-clinic translation of
experimental therapeutics in stroke. Hence, designing
studies that dovetail on tPA’s safety and efficacy profile,
but also recognize the drug’s limitations and adverse
effects may prove to be advantageous for stroke therapy.
In parallel, investigations into novel neuroprotective
drugs that may be efficacious beyond the 3-hour
window after stroke can also benefit many stroke
patients. In 2002, Watterson and colleagues [82] sug-
gested, based on their earlier time course analysis [83] of
post-ischemia activity changes in the death associated
protein kinase (DAPK) and the attenuation of neurologic
sequelae resulting from treatment with DAPK inhibitors
during the post-injury time windows of 6 h or later [84],
that DAPK may be a viable therapeutic target for stroke.
Because of the significant unmet need in stroke for a
delayed post-injury treatment schedules that might reduce
longer-term neuronal loss, such neuroprotective regimens
have the potential to contribute to improved outcomes in
this disease. Using both in vitro and in vivo models of
stroke, we recently obtained encouraging results revealing
the robust neuroprotective effects of the protein kinase
inhibitors targeting other events that peak during the 6–12-
h post-ischemia time window. Significant reductions in
stroke-induced histological and behavioral deficits were
observed compared with animals suffering stroke that
received a vehicle treatment alone. Shamloo and colleagues
subsequently reported neuroprotective effects of the
DAPK inhibitor developed by Watterson and coworker
in both in vitro and in vivo stroke models using an
experimental paradigm of DAPK inhibitor treatment
initiated prior to and during stroke induction [85]. More
recently, Snyder and colleagues [86] demonstrated that
NMDA-induced excitotoxicity of cultured neurons defi-
cient in DANGER, a partial MAB-21 domain-containing
protein that binds directly to DAPK and inhibits DAPK
catalytic activity, displayed significantly greater DAPK
activity and increased cell death than wild-type control
cells. They also reported that DANGER-deficient mice
showed significantly more severe brain damage after acute
injury than control mice. Therefore, both genetic and
pharmacological approaches demonstrate that conditions
characterized by inhibition of DAPK activity, either hours
post-ischemia when DAPK activity reaches its peak of
activity or coincident with ischemia induction, protect
against subsequent neuronal loss. Altogether, a growing
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body of literature and ongoing studies indicate a pivotal
role for DAPK in the physiological control of neuronal
survival and pathophysiological role in neuronal death that
can be attenuated by selective DAPK inhibition, thereby
raising interest in addressing its potential as a novel target
for stroke therapeutics. We envision that the timing of
therapeutic treatments in the 6–9-h period after stroke
induction corresponding to the peak time point of
upregulation of DAPK enzyme activity, inflammatory
genes and neurotoxic proteins as a viable therapeutic time
window for treatments that attenuate events contributing
to the exacerbation of secondary cell death in stroke.
Being cognizant of the limited therapeutic window of tPA,
finding an effective treatment beyond 3 h, such as the
proposed DAPK inhibitor treatment, should greatly increase
the target population of stroke patients who could benefit from
this therapy. In the same vein, other neuroprotective drugs
such as albumin and minocycline as well as the FDA-
approved drug tPA, can be tested with stem cells using a
combination of STEPS and STAIR criteria.
Conclusions
EPCs represent a population of cells critical for angiogenesis
and vasculogenesis, thus they may play a critical role in BBB
repair following stroke. The preclinical results have been
encouraging, and the transplantation of stem cells, including
EPCs, for stroke therapy is rapidly being translated into
clinical trials [87, 88]. Over the last 5 years, recommenda-
tions to better guide the successful entry of stem cell therapy
into the clinic have received continuing critical assessments
from meetings involving leaders from academia, industry,
NIH, and the FDA [1–3]. The mechanism of action
underlying cell therapy remains to be fully determined. The
optimal timing, route of injection, and dosage for EPC
transplantation are also not fully understood. These persisting
gaps in our knowledge should be seriously considered in
order to achieve a clinically relevant estimate of the risk-
to-benefit ratio of cell therapy for stroke. The initiation of
clinical trials implementing EPC transplantation as a
therapeutic regimen for stroke needs to be preceded by
systematically designed translational preclinical studies to
provide rigorous inquiry into the safety and efficacy of
EPCs. Future studies are also planned in combining
DAPK inhibitors and stem cell transplantation for stroke
therapy. With the EPCs exerting indirect anti-inflammatory
effects (via repair of the BBB thereby suppressing access
of the inflammatory cells to the ischemic brain) and with
small molecule inhibitors also affording anti-inflammatory
modulation, the combination of these two types of novel
treatments may synergistically arrest a major secondary
cell death process associated with stroke.
Acknowledgments The Watterson Laboratory is supported in part
by NIH awards R01NS056051 and R01AG031311 and funds from the
Alzheimer’s Drug Discovery Foundation. Northwestern University
has patented and licensed to industry novel drugs developed in the
DMW laboratory. The Borlongan Laboratory is supported by James
and Esther King Foundation for Biomedical Research Program, USF
Signature Program in Interdisciplinary Neuroscience, SanBio Inc.,
Celgene Cellular Therapeutics, KMPHC, NeuralStem Inc., NIH
NINDS UO15U01NS055914-04, and NIH NINDS R01NS071956-
01. CVB has patents and pending patents on cell therapy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Borlongan CV, Chopp M, Steinberg GK, Bliss TM, Li Y, Lu M, et
al. Potential of stem/progenitor cells in treating stroke: the missing
steps in translating cell therapy from laboratory to clinic. Regen
Med. 2008;3:249–50.
2. Chopp M, Steinberg GK, Kondziolka D, Lu M, Bliss TM, Li Y, et
al. Who’s in favor of translational cell therapy for stroke: STEPS
forward please? Cell Transplant. 2009;18:691–3.
3. Stem Cell Therapies as an Emerging Paradigm in Stroke
Participants. Stem Cell Therapies as an Emerging Paradigm in
Stroke (STEPS): bridging basic and clinical science for cellular
and neurogenic factor therapy in treating stroke. Stroke.
2009;40:510–5.
4. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR,
Gebel J, et al. Transplantation of cultured human neuronal cells
for patients with stroke. Neurology. 2000;55:565–9.
5. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem
cells. Blood. 2003;102:3483–93.
6. Munoz-Elias G, Woodbury D, Black IB. Marrow stromal cells,
mitosis, and neuronal differentiation: stem cell and precursor
function. Stem Cells. 2003;21:437–48.
7. Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu
SJ, et al. Neural progenitor NT2N cell lines from teratocar-
cinoma for transplantation therapy in stroke. Prog Neurobiol.
2008;85:318–34.
8. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke.
Expert Rev Neurother. 2008;8:1193–201.
9. Hess DC, Borlongan CV. Stem cells and neurological diseases.
Cell Prolif. 2008;1:94–114.
10. Lapidot T, Kollet O. The brain–bone–blood triad: traffic lights for
stem-cell homing and mobilization. Hematol Am Soc Hematol
Educ Program. 2010;2010:1–6.
11. Lapidot T, Dar A, Kollet O. How do stem cells find their way
home? Blood. 2005;106:1901–10.
12. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem
cell mobilization. J Cell Biochem. 2006;99:690–70.
13. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem
cells in motion. Blood. 2008;111:3923–30.
14. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4
interactions between hematopoietic and bone marrow stromal cells
regulate human stem cell migration and development in NOD/
SCID chimeric mice. Exp Hematol. 2006;34:967–75.
15. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development
of fibroblast colonies in monolayer cultures of guinea-pig bone
marrow and spleen cells. Tissue Kinet. 1997;3:393–403.
16. Gronthos S, Simmons PJ. The biology and application of human
bone marrow stromal cell precursors. J Hematother. 1996;5:15–23.
96 Transl. Stroke Res. (2012) 3:90–98
17. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on
human marrow-derived mesenchymal cells are detected by
monoclonal antibodies. Bone. 1992;13:69–80.
18. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal
progenitors from human bone marrow differentiate in vitro
according to a hierarchical model. J Cell Sci. 2000;113:1161–6.
19. Pereira RF, O’Hara MD, Laptev AV, Halford KW, Pollard MD,
Class R, et al. Marrow stromal cells as a source of progenitor cells
for nonhematopoietic tissues in transgenic mice with a phenotype
of osteogenesis imperfecta. Proc Natl Acad Sci USA.
1999;95:1142–7.
20. Prockop DJ. Marrow stromal cells as stem cells for nonhemato-
poietic tissues. Science. 1997;276:71–4.
21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
et al. Isolation of putative progenitor endothelial cells for
angiogenesis. Science. 1997;275:964–7.
22. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M,
et al. Bone marrow origin of endothelial progenitor cells
responsible for postnatal vasculogenesis in physiological and
pathological neovascularization. Circ Res. 1999;85:221–8.
23. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR,
et al. Recruitment of stem and progenitor cells from the bone
marrow niche requires MMP-9 mediated release of kit-ligand.
Cell. 2002;109:625–37.
24. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating
endothelial cells and endothelial outgrowth from blood. J Clin
Invest. 2000;105:71–7.
25. McCarty JH. Cell adhesion and signaling networks in brain
neurovascular units. Curr Opin Hematol. 2009;16:209–14.
26. Lapergue B, Mohammad A, Shuaib A. Endothelial progenitor
cells and cerebroascular diseases. Prog Neurobiol. 2007;83:349–
62.
27. Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K,
Otem M, et al. In vitro differentiation of endothelial cells from
AC133-positive progenitor cells. Blood. 2000;95:3106–12.
28. Rustemeyer P, Wittkowski W, Jurk K, Koller A. Optimized flow
cytometric analysis of endothelial progenitor cells in peripheral
blood. J Immunoass Immunochem. 2006;27:77–88.
29. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M,
et al. Ischemia- and cytokine-induced mobilization of bone
marrow-derived endothelial progenitor cells for neovasculariza-
tion. Nat Med. 1999;5:434–8.
30. Kocher AA, Schuster MD, Bonaros N, Lietz K, Xiang G, Martens
TP, et al. Myocardial homing and neovascularization by human
bone marrow angioblasts is regulated by IL-8/Gro CXC chemo-
kines. J Mol Cell Cardiol. 2006;40:455–64.
31. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central
nervous system entry of peripherally injected umbilical cord blood
cells is not required for neuroprotection in stroke. Stroke.
2004;35:2385–9.
32. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-
renewal, and the osteogenic potential of purified human mesen-
chymal stem cells during extensive subcultivation and following
cryopreservation. J Cell Biochem. 1997;64:278–94.
33. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, et al. Cell
and gene therapy using mesenchymal stem cells (MSCs). J
Autoimmun. 2008;30:121–7.
34. Sordi V, Piemonti L. Mesenchymal stem cells as feeder cells for
pancreatic islet transplants. Rev Diabetes Stud. 2010;7:132–43.
35. Hamada S, Satoh K, Hirota M, Kanno A, Umino J, Ito H, et al.
The homeobox gene MSX2 determines chemosensitivity of
pancreatic cancer cells via the regulation of transporter gene
ABCG2. J Cell Physiol. 2011;(in press).
36. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda
R, Quarto R. Proliferation kinetics and differentiation potential
of ex vivo expanded human bone marrow stromal cells:
implications for their use in cell therapy. Exp Hematol.
2000;28:707–15.
37. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham
JD, Bundoc VG, et al. Bone marrow stromal cells use TGF-beta to
suppress allergic responses in a mouse model of ragweed-induced
asthma. Proc Natl Acad Sci USA. 2010;107:5652–7.
38. Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens
UM. Lack of telomerase activity in human mesenchymal stem
cells. Leukemia. 2003;17:1146–9.
39. Wang D, Shen W, Zhang F, Chen M, Chen H, Cao K. Connexin43
promotes survival of mesenchymal stem cells in ischaemic heart.
Cell Biol Int. 2010;34:415–23.
40. Liang H, Hou H, Yi W, Yang G, Gu C, Lau WB, et al. Increased
expression of pigment epithelium-derived factor in aged mesen-
chymal stem cells impairs their therapeutic efficacy for attenuating
myocardial infarction injury. Eur Heart J. 2011;(in press)
41. Ko IK, Kim BG, Awadallah A, Mikulan J, Lin P, Letterio JJ, et al.
Targeting improves MSC treatment of inflammatory bowel
disease. Mol Ther. 2010;18:1365–72.
42. Kobune M, Kawano Y, Ito Y, Chiba H, Nakamura K, Tsuda H, et
al. Telomerized human multipotent mesenchymal cells can
differentiate into hematopoietic and cobble-stone area-supporting
cells. Exp Hematol. 2003;31:715–22.
43. Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. Serum
deprivation of human marrow stromal cells (hMSCs) selects for a
subpopulation of early progenitor cells with enhanced expression
of OCT-4 and other embryonic genes. Blood. 2004;103:1647–52.
44. Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of
oxidative damage in multiple sclerosis and a cell therapy approach
to treatment. Autoimmune Dis. 2011, 164608.
45. Sokal EM. From hepatocytes to stem and progenitor cells for liver
regenerative medicine: advances and clinical perspectives. Cell
Prolif. 2011;44:39–43.
46. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M,
Ratajczak J, et al. A population of very small embryonic-like
(VSEL) CXCR4 (+) SSEA-1(+)Oct-4+ stem cells identified in
adult bone marrow. Leukemia. 2006;20:857–69.
47. Zuba-Surma EK, KuciaM,WuW, Klich I, Lillard Jr JW, Ratajczak J,
et al. Very small embryonic-like stem cells are present in adult murine
organs: Image Stream-based morphological analysis and distribution
studies. Cytometry A. 2008;73A:1116–27.
48. Kucia M, Halasa M, Wysoczynski M, Baskiewicz-Masiul M,
Moldenhawer S, Zuba-Surma E, et al. Morphological and
molecular characterization of novel population of CXCR4+
SSEA-4+ Oct-4+ very small embryonic-like cells purified
from human cord blood: preliminary report. Leukemia.
2007;21:297–303.
49. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal
stem cell transplantation in stroke patients. Ann Neurol.
2005;57:874–82.
50. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic
benefit of intracerebral transplantation of bone marrow stromal
cells after cerebral ischemia in rats. J Neurol Sci. 2001;189:49–57.
51. Chen J, Wang L, Zhang Z, Lu D, Lu M, Chopp M. Therapeutic
benefit of intravenous administration of bone marrow stromal
cells after cerebral ischemia in rats. Stroke. 2001;32:1005–11.
52. Chopp M, Li Y. Treatment of neural injury with marrow stromal
cells. Lancet Neurol. 2002;1:92–100.
53. Li Y, Chen J, Chopp M. Adult bone marrow transplantation after
stroke in adult rats. Cell Transplant. 2001;10:31–40.
54. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, et al. Human
marrow stromal cell therapy for stroke in rat: Neurotrophins and
functional recovery. Neurology. 2002;59:514–23.
55. Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M, et al.
Gliosis and brain remodeling after treatment of stroke in rats with
marrow stromal cells. Glia. 2005;49:407–17.
Transl. Stroke Res. (2012) 3:90–98 97
56. Rempe DA, Kent TA. Using bone marrow stromal cells for
treatment of stroke. Neurology. 2002;59:486–7.
57. Song S, Kamath S, Mosquera D, Zigova T, Sanberg P, Vesely DL,
et al. Expression of brain natriuretic peptide by human bone
marrow stromal cells. Exp Neurol. 2004;185:191–7.
58. Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G, et al.
Transplantation of bone marrow-derived stem cells: a promising
therapy for stroke. Cell Transplant. 2007;16:159–69.
59. Kucia M, Ratajczak J, Ratajczak MZ. Are bone marrow stem cells
plastic or heterogenous—that is the question. Exp Hematol.
2005;33:613–23.
60. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al.
Isolation and transplantation of autologous circulating endothelial
cells into denuded vessels and prosthetic grafts: Implications for
cell- based vascular therapy. Circulation. 2003;108:2710–5.
61. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Egucji H, et al.
Transplanted cord blood-derived endothelial precursor cells augment
postnatal neovascularization. J Clin Invest. 2000;105:1527–36.
62. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M,
et al. Expression of VEGFR-2 and AC133 by circulating human
CD34(+) cells identifies a population of functional endothelial
precursors. Blood. 2000;95:952–8.
63. Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Tervaert JW,
Lodder J. Endothelial progenitor cell research in stroke: a
potential shift in pathophysiological and therapeutical concepts.
Stroke. 2008;39:2158–65.
64. Nishimura N, Schaffer CB, Friedman B, Tsai PS, Lyden PD,
Kleinfeld D. Targeted insult to subsurface cortical blood vessels
using ultrashort laser pulses: three models of stroke. Nat Methods.
2006;3:99–108.
65. Rivers CS, Wardlaw JM, Armitage PA, Bastin ME, Carpenter TK,
Cvoro V, et al. Persistent infarct hyperintensity on diffusion-
weighted imaging late after stroke indicates heterogeneous,
delayed, infarct evolution. Stroke. 2006;37:1418–23.
66. Ay H, Arsava EM, Rosand J, Furie KL, Singhal AB, Schaefer PW,
et al. Severity of leukoaraiosis and susceptibility to infarct growth
in acute stroke. Stroke. 2008;39:1409–13.
67. Stoeckel MC, Wittsack HJ, Meisel S, Seitz RJ. Pattern of cortex
and white matter involvement in severe middle cerebral artery
ischemia. J Neuroimaging. 2007;17:131–40.
68. Hristov M, Weber C. Endothelial progenitor cells: characteriza-
tion, pathophysiology, and possible clinical relevance. J Cell Mol
Med. 2004;8:498–508.
69. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K,
Nagatsuka K, et al. Circulating cd34-positive cells provide an
index of cerebrovascular function. Circulation. 2004;109:2972–5.
70. Ingram DA, Caplice NM, Yoder MC. Unresolved questions,
changing definitions, and novel paradigms for defining endothe-
lial progenitor cells. Blood. 2005;106:1525–31.
71. Schatteman GC, Awad O. Hemangioblasts, angioblasts, and adult
endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol
Biol. 2004;276:13–21.
72. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev
Med. 2005;56:79–101.
73. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA,
McEver RP, et al. Endothelial cells in physiology and in the
pathophysiology of vascular disorders. Blood. 1998;91:3527–61.
74. Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et
al. Endothelial progenitor cells during cerebrovascular disease.
Stroke. 2005;36:151–3.
75. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA,
Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular
function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.
76. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott
RB, Emerich DF. Intracerebral transplantation of porcine choroid
plexus provides structural and functional neuroprotection in a
rodent model of stroke. Stroke. 2004;35:2206–10.
77. Bliss TM, Kelly S, Shah AK, Foo WC, Kohli P, Stokes C, et al.
Transplantation of hNT neurons into the ischemic cortex: cell
survival and effect on sensorimotor behavior. J Neurosci Res.
2006;83:1004–14.
78. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, et al.
Niaspan increases angiogenesis and improves functional recovery
after stroke. Ann Neurol. 2007;62:49–58.
79. Manaenko A, Chen H, Kammer J, Zhang JH, Tang J. Comparison
Evans Blue injection routes: Intravenous versus intraperitoneal,
for measurement of blood-brain barrier in a mice hemorrhage
model. J Neurosci Methods. 2011;195:206–10.
80. ChoppM, Zhang ZG, JiangQ. Neurogenesis, angiogenesis, andMRI
indices of functional recovery from stroke. Stroke. 2007;38:827–31.
81. Guzman R, Uchida N, Bliss TM, He D, Christopherson KK,
Stellwagen D, et al. Long-term monitoring of transplanted human
neural stem cells in developmental and pathological contexts with
MRI. Proc Natl Acad Sci USA. 2007;104:10211–6.
82. Schumacher AM, Velentza AV, Watterson DM. Death-associated
protein kinase as a potential therapeutic target. Expert Opin Ther
Targets. 2002;6:497–506.
83. Schumacher AM, Velentza AV, Watterson DM, Wainwright MS.
DAPK catalytic activity in the hippocampus increases during the
recovery phase in an animal model of brain hypoxic-ischemic
injury. Biochim Biophys Acta. 2002;1600:128–37.
84. Velentza AV,Wainwright MS, Zasadzki M, Mirzoeva S, Schumacher
AM, Haiech J, et al. An aminopyridazine-based inhibitor of a pro-
apoptotic protein kinase attenuates hypoxia-ischemia induced acute
brain injury. Bioorg Med Chem Lett. 2003;13:3465–70.
85. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg
D. Death-associated protein kinase is activated by dephosphorylation
in response to cerebral ischemia. J Biol Chem. 2005;280:42290–9.
86. Kang BN, Ahmad AS, Saleem S, Patterson RL, Hester L, Dore S,
et al. Death-associated protein kinase-mediated cell death modu-
lated by interaction with DANGER. J Neurosci. 2010;30:93–8.
87. Borlongan CV. Bone marrow stem cell mobilization in stroke: a
‘bonehead’ may be good after all! Leukemia. 2011. doi:10.1038/
leu.2011.167.
88. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The
great migration of bone marrow-derived stem cells toward the
ischemic brain: Therapeutic implications for stroke and other
neurological disorders. Prog Neurobiology. 2011;(in press).
98 Transl. Stroke Res. (2012) 3:90–98
